1. "Hematologic Malignancies Research"
  2. "Anas Younes"
Formats
  1. Meeting Abstract (22)
  2. Journal Article (11)
Groups
  1. Center for Hematologic Malignancies (33)
  2. Department of Medicine (33)
  3. Executive Committee, Center for Hematologic Malignancies (33)
  4. GSK Faculty (33)
  5. Hematologic Malignancies Research (33)
  6. Hematologic Malignancies, Division of (33)

More Groups

People
  1. Anas Younes (33)
  2. Connie Batlevi (19)
  3. Maria Palomba (19)
  4. Andrew Intlekofer (18)
  5. Andrew Zelenetz (16)
  6. Venkatraman Seshan (15)

More People

Years
  1. 2023 (1)
  2. 2022 (2)
  3. 2021 (1)
  4. 2020 (2)
  5. 2019 (6)
  6. 2018 (2)

More Years

Publications
  1. Blood (16)
  2. Hematological Oncology (2)
  3. Journal of Clinical Oncology (2)
  4. Nature Reviews Clinical Oncology (2)
  5. Biology of Blood and Marrow Transplantation (1)
  6. Blood Cancer Journal (1)

More Publications

Publishers
  1. American Society of Hematology (16)
  2. Nature Publishing Group (5)
  3. American Society of Clinical Oncology (2)
  4. Wiley Blackwell (2)
  5. Amer Soc Clinical Investigation Inc (1)
  6. American Association for Cancer Research (1)

More Publishers

Results (33)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPĪ± checkpoint blocker
    Journal Article

    Dacek, M. M.; Kurtz, K. G.; Wallisch, P.; Pierre, S. A.; Khayat, S.; Bourne, C. M.; Gardner, T. J.; Vogt, K. C.; Aquino, N.; Younes, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma
    Journal Article

    Erazo, T.; Evans, C. M.; Zakheim, D.; Chu, K. L.; Refermat, A. Y.; Asgari, Z.; Yang, X.; Da Silva Ferreira, M.; Mehta, S.; Russo, M. V.; more...
    Nature Communications (2022)

    Fulltext@MSK | Save
  • TP53 mutations and RNA binding protein MUSASHI 2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma
    Meeting Abstract

    Erazo, I. T.; Evans, C. M.; Zakheim, D.; Chu, K. L.; Barbash, O.; Refermat, A. Y.; Batlevi, C. L.; Younes, A.; Kharas, M. G.
    Blood (2021)

    Fulltext@MSK | Save
  • Alternative anti-CD20 antibody versus desensitization for lymphoma patients with drug hypersensitivity reactions requiring discontinuation of rituximab, obinutuzumab, or ofatumumab
    Meeting Abstract

    Ghione, P.; Joffe, E.; De Paola, N.; Mainardi, T.; Noor, S. J.; Bobillo, S.; Myskowski, P. L.; Palomba, M. L.; Moskowitz, A. J.; Mato, A. R.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma
    Journal Article

    Mondello, P.; Tadros, S.; Teater, M.; Fontan, L.; Chang, A. Y.; Jain, N.; Yang, H.; Singh, S.; Ying, H. Y.; Chu, C. S.; more...
    Cancer Discovery (2020)

    Fulltext@MSK | Save
  • Retrospective analysis of gemcitabine and oxaliplatin (GemOx)-based treatment in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
    Meeting Abstract

    Schade, J. R.; Kim, C.; Drill, E.; Qiu, A.; Batlevi, C. L.; Caron, P.; Colbourn, D. S.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Thirty day resource utilization after chimeric antigen receptor (CAR) T cell infusion for hematologic malignancies
    Meeting Abstract

    Shah, G. L.; Park, J.; Sauter, C. S.; Duck, E.; Halton, E.; Batlevi, C. W.; Palomba, M. L.; Younes, A.; Geyer, M. B.; Smith, E.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Paradigms for precision medicine in epichaperome cancer therapy
    Journal Article

    Pillarsetty, N.; Jhaveri, K.; Taldone, T.; Caldas-Lopes, E.; Punzalan, B.; Joshi, S.; Bolaender, A.; Uddin, M. M.; Rodina, A.; Yan, P.; more...
    Cancer Cell (2019)

    Fulltext@MSK | Save